Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Chamarthi, Bindu ^a,b,c   Gaziano, J Michael ^a,b,d   Blonde, Lawrence ^e   Vinik, Aaron ^f   Scranton, Richard E ^c   Ezrokhi, Michael ^c   Rutty, Dean ^g   Cincotta, Anthony H ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VeroScience LLC   (United States)

^d Veterans Afairs Healthcare System   (United States)

^e OCHSNER MEDICAL CENTER   (United States)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^g Everest Clinical Research Services Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DYSGLYCEMIA; FATIGUE; FEMALE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT CHANGE; AGED; ANALYSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; BROMOCRIPTINE; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84929329277     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/157698     Document Type: Article

References (53)

1. W. B. Kannel and D. L. McGee, "Diabetes and cardiovascular disease. The Framingham Study", The Journal of the American Medical Association, vol. 241, no. 19, pp. 2035-2038, 1979.
2. M. J. Sheetz and G. L. King, "Molecular understanding of hyperglycemia's adverse effects for diabetic complications", The Journal of the American Medical Association, vol. 288, no. 20, pp. 2579-2588, 2002.
3. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group, "Effects of intensive glucose lowering in type 2 diabetes", The New England Journal of Medicine, vol. 358, pp. 2545-2559, 2008.
5. A. Patel, S. MacMahon, J. Chalmers et al., "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes", The New England Journal of Medicine, vol. 358, no. 24, pp. 2560-2572, 2008.
6. W. Duckworth, C. Abraira, T. Moritz et al., "Glucose control and vascular complications in veterans with type 2 diabetes", The New England Journal of Medicine, vol. 360, no. 2, pp. 129-139, 2009.
7. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, "10-Year follow-up of intensive glucose control in type 2 diabetes", The New England Journal of Medicine, vol. 359, no. 15, pp. 1577-1589, 2008.
8. H. C. Gerstein, M. E. Miller, F. Ismail-Beigi et al., "Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial", The Lancet, vol. 384, no. 9958, pp. 1936-1941, 1936.
9. M. C. Riddle, W. T. Ambrosius, D. J. Brillon et al., "Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial", Diabetes Care, vol. 33, no. 5, pp. 983-990, 2010.
10. S. Zoungas, J. Chalmers, T. Ninomiya et al., "Association of HbA1? levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds", Diabetologia, vol. 55, no. 3, pp. 636-643, 2012.
11. Y. Chen, Y. Huang, X. Li et al., "Association of arterial stifness with HbA1c in 1, 000 type 2 diabetic patients with or without hypertension", Endocrine, vol. 36, no. 2, pp. 262-267, 2009.
12. E. Selvin, S. Marinopoulos, G. Berkenblit et al., "Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus", Annals of Internal Medicine, vol. 141, no. 6, pp. 421-431, 2004.
13. E. Selvin, J. Coresh, S. H. Golden, L. L. Boland, F. L. Brancati, and M. W. Stefes, "Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study", Diabetes Care, vol. 28, no. 8, pp. 1965-1973, 2005.
14. Y. Zhang, G. Hu, Z. Yuan, and L. Chen, "Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis", PLoS ONE, vol. 7, no. 8, Article ID e42551, 2012.
15. J. E. B. Reusch and C. C. Wang, "Cardiovascular disease in diabetes: where does glucose ft in?" Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 8, pp. 2367-2376, 2011.
16. G. Grassi, "Sympathetic overdrive and cardiovascular risk in the metabolic syndrome", Hypertension Research, vol. 29, no. 11, pp. 839-847, 2006.
17. G. W. Lambert, N. E. Straznicky, E. A. Lambert, J. B. Dixon, and M. P. Schlaich, "Sympathetic nervous activation in obesity and the metabolic syndrome-causes, consequences and therapeutic implications", Pharmacology & Therapeutics, vol. 126, no. 2, pp. 159-172, 2010.
18. N. Tentolouris, S. Liatis, and N. Katsilambros, "Sympathetic system activity in obesity and metabolic syndrome", Annals of the New York Academy of Sciences, vol. 1083, pp. 129-152, 2006.
19. R. Kietadisorn, R. P. Juni, and A. L. Moens, "Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities", The American Journal of Physiology-Endocrinology and Metabolism, vol. 302, no. 5, pp. E481-E495, 2012.
20. F. Santilli, F. Cipollone, A. Mezzetti, and F. Chiarelli, "The role of nitric oxide in the development of diabetic angiopathy", Hormone and Metabolic Research, vol. 36, no. 5, pp. 319-335, 2004.
21. A. Magenta, S. Greco, M. C. Capogrossi, C. Gaetano, and F. Martelli, "Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction", BioMed Research International, vol. 2014, Article ID 193095, 16 pages, 2014.
22. F. Franchi, C. Lazzeri, G. Barletta, L. Ianni, and M. Mannelli, "Centrally mediated effects of bromocriptine on cardiac sympathovagal balance", Hypertension, vol. 38, no. 1, pp. 123-129, 2001.
23. J. R. Sowers, M. S. Golub, M. E. Berger, and L. A. Whitfeld, "Dopaminergic modulation of pressor and hormonal responses in essential hypertension", Hypertension, vol. 4, no. 3, pp. 424-430, 1982.
24. J. M. Gaziano, A. H. Cincotta, C. M. O'Connor et al., "Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes", Diabetes Care, vol. 33, no. 7, pp. 1503-1508, 2010.
25. J. M. Gaziano, A. H. Cincotta, A. Vinik, L. Blonde, N. Bohannon, and R. Scranton, "Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects", Journal of the American Heart Association, vol. 1, no. 5, Article ID e002279, 2012.
26. R. A. Defronzo, "Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes", Diabetes Care, vol. 34, pp. 789-794, 2011.
27. A. I. Vinik, A. H. Cincotta, R. E. Scranton, N. Bohannon, M. Ezrokhi, and J. M. Gaziano, "Effect of Bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents", Endocrine Practice, vol. 18, no. 6, pp. 931-943, 2012.
28. A. J. Garber, L. Blonde, Z. T. Bloomgarden, Y. Handelsman, and S. Dagogo-Jack, "The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations", Endocrine Practice, vol. 19, no. 1, pp. 100-106, 2013.
29. S. Luo, J. Luo, A. H. Meier, and A. H. Cincotta, "Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance", Neuroreport, vol. 8, no. 16, pp. 3495-3499, 1997.
30. S. Luo, Y. Liang, and A. H. Cincotta, "Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters", Neuroendocrinology, vol. 69, no. 3, pp. 160-166, 1999.
31. S. Luo, J. Luo, and A. H. Cincotta, "Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance", Neuroendocrinology, vol. 70, no. 6, pp. 460-465, 1999.
32. S. Luo, J. Luo, and A. H. Cincotta, "Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters", NeuroReport, vol. 10, no. 10, pp. 2073-2077, 1999.
33. M. Ezrokhi, S. Luo, Y. Trubitsyna, and A. H. Cincotta, "Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats", Diabetology & Metabolic Syndrome, vol. 6, no. 1, p. 104, 2014.
34. M. Ezrokhi, Y. Trubitsyna, S. Luo, and A. H. Cincotta, "Timed dopamine agonist treatment ameliorates both vascular nitrosative/oxidative stress pathology and aortic stiffiness in arteriosclerotic, hypertensive SHR rats [abstract]", Diabetes, vol. 59, supplement 1, p. A67, 2010.
35. A. H. Cincotta, "Hypothalamic role in insulin resistance and insulin resistance syndrome", in Frontiers in Animal Diabetes Research, B. Hansen and E. Shafrir, Eds., pp. 271-312, Taylor & Francis, London, UK, 2002.
36. M. Ezrokhi, S. Luo, Y. Trubitsyna, and A. H. H. Cincotta, "Weighted effects of bromocriptine treatment on glucose homeostasis during hyperglycemic versus euglycemic clamp conditions in insulin resistant hamsters: bromocriptine as a unique postprandial insulin sensitizer", Journal of Diabetes & Metabolism, supplement 2, article 007, 2012.
37. C. M. McEniery, S. Wallace, I. S. Mackenzie et al., "Increased ambulatory pulse pressure is a strong risk factor for coronary endothelial vasomotor dysfunction", Journal of the American College of Cardiology, vol. 45, pp. 1461-1466, 2005.
38. A. K. Gupta, E. Ravussin, D. L. Johannsen, A. J. Stull, W. T. Cefalu, and W. D. Johnson, "Endothelial dysfunction: an early cardiovascular risk marker in asymptomatic obese individuals with prediabetes", British Journal of Medicine and Medical Research, vol. 2, no. 3, pp. 413-423, 2012.
39. A. H. Cincotta, A. H. Meier, and M. Cincotta Jr., "Bromocriptine improves glycaemic control and serum lipid profle in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes", Expert Opinion on Investigational Drugs, vol. 8, no. 10, pp. 1683-1707, 1999.
40. J. M. Monti and D. Monti, "The involvement of dopamine in the modulation of sleep and waking", Sleep Medicine Reviews, vol. 11, no. 2, pp. 113-133, 2007.
41. A. H. Cincotta and A. H. Meier, "Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus)", Metabolism: Clinical and Experimental, vol. 44, no. 10, pp. 1349-1355, 1995.
42. H. Pijl, S. Ohashi, M. Matsuda et al., "Bromocriptine: a novel approach to the treatment of type 2 diabetes", Diabetes Care, vol. 23, no. 8, pp. 1154-1161, 2000.
43. Y. Liang, M. Lubkin, H. Sheng, P. W. D. Scislowski, and A. H. Cincotta, "Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice", Biochimica et Biophysica Acta, vol. 1405, no. 1-3, pp. 1-13, 1998.
44. A. H. Meier and A. H. Cincotta, "Circadian rhythms regulate the expression of the thrify genotype/phenotype", Diabetes Reviews, vol. 4, no. 4, pp. 464-487, 1996.
45. C. P. Coomans, S. A. A. Van Den Berg, E. A. Lucassen et al., "The suprachiasmatic nucleus controls circadian energy metabolism and hepatic insulin sensitivity", Diabetes, vol. 62, no. 4, pp. 1102-1108, 2013.
46. J. Bass and J. S. Takahashi, "Circadian integration of metabolism and energetics", Science, vol. 330, no. 6009, pp. 1349-1354, 2010.
47. E. van de Giessen, F. Celik, D. H. Schweitzer, W. van den Brink, and J. Booij, "Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity", Journal of Psychopharmacology, vol. 28, no. 9, pp. 866-873, 2014.
48. I. Chiodini, G. Adda, A. Scillitani et al., "Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications", Diabetes Care, vol. 30, no. 1, pp. 83-88, 2007.
49. I. J. Elenkov, R. L. Wilder, G. P. Chrousos, and E. S. Vizi, "The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system", Pharmacological Reviews, vol. 52, no. 4, pp. 595-638, 2000.
50. A. Hu, X. Jiao, E. Gao et al., "Chronic β-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/reperfusion injury by provoking inducible nitricoxide synthase-mediated nitrative stress", Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 2, pp. 469-475, 2006.
51. L. M. Davis, Z. Pei, M. A. Trush et al., "Bromocriptine reduces steatosis in obese rodent models", Journal of Hepatology, vol. 45, no. 3, pp. 439-444, 2006.
52. V. S. Nade, L. A. Kawale, U. B. Todmal, and A. B. Tajanpure, "Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats", Indian Journal of Pharmacology, vol. 44, no. 6, pp. 688-693, 2012.
53. R. M. Carey, G. R. van Loon, A. D. Baines, and D. L. Kaiser, "Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man", Journal of Clinical Endocrinology and Metabolism, vol. 56, no. 3, pp. 595-602, 1983.